Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities
Author:
Liu Shelan1, Kang Min2, Zhao Na3, Zhuang Yali2, Li Shijian4, Song Tie2ORCID
Affiliation:
1. Department of Infectious Diseases , Zhejiang Provincial Centre for Disease Control and Prevention , Hangzhou , Zhejiang Province , China 2. Guangdong Provincial Centre for Disease Control and Prevention , Guangzhou , Guangdong Province , China 3. School of Ecology and Environment, Anhui Normal University , Wuhu , Anhui Province , China 4. Department of Public Health, SUNY Old Westbury , New York , USA
Abstract
Abstract
Currently, people all over the world have been affected by coronavirus disease 2019 (COVID-19). Fighting against COVID-19 is the top priority for all the countries and nations. The development of a safe and effective COVID-19 vaccine is considered the optimal way of ending the pandemic. Three hundred and 44 vaccines were in development, with 149 undergoing clinical research and 35 authorized for emergency use as to March 15 of 2022. Many studies have shown the effective role of COVID-19 vaccines in preventing SARS-CoV-2 infections as well as serious and fatal COVID-19 cases. However, tough challenges have arisen regarding COVID-19 vaccines, including long-term immunity, emerging COVID-19 variants, and vaccine inequalities. A systematic review was performed of recent COVID-19 vaccine studies, with a focus on vaccine type, efficacy and effectiveness, and protection against SARS-CoV-2 variants, breakthrough infections, safety, deployment and vaccine strategies used in the real-world. Ultimately, there is a need to establish a unified evaluation standard of vaccine effectiveness, monitor vaccine safety and effectiveness, along with the virological characteristics of SARS-CoV-2 variants; and determine the most useful booster schedule. These aspects must be coordinated to ensure timely responses to beneficial or detrimental situations. In the future, global efforts should be directed toward effective and immediate vaccine allocations, improving vaccine coverage, SARS-CoV-2 new variants tracking, and vaccine booster development.
Funder
National Natural Science Foundation of China Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents
Publisher
Walter de Gruyter GmbH
Reference151 articles.
1. Zhu, N, Zhang, D, Wang, W, Li, X, Yang, B, Song, J, et al.. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. 2. Verity, R, Okell, LC, Dorigatti, I, Winskill, P, Whittaker, C, Imai, N, et al.. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20:669–77. 3. Wang, D, Hu, B, Hu, C, Zhu, F, Liu, X, Zhang, J, et al.. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9. 4. Zhang, W, Wu, X, Zhou, H, Xu, F. Clinical characteristics and infectivity of asymptomatic carriers of SARS-CoV-2 (Review). Exp Ther Med 2021;21:115. 5. Oran, DP, Topol, EJ. The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review. Ann Intern Med 2021;174:655–62.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|